RecruitingNCT06379152

Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction

Sponsor

Chongqing Medical University

Enrollment

400 participants

Start Date

Sep 20, 2020

Study Type

OBSERVATIONAL

Conditions

Heart Failure With Preserved Ejection Fraction Prognathism

Summary

Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study examines whether bilirubin levels in the blood (a substance produced when red blood cells break down) can predict how patients with a type of heart failure called heart failure with preserved ejection fraction (HFpEF) will do over time. **You may be eligible if...** - You are 18 or older - You have been diagnosed with HFpEF (a form of heart failure where the heart squeezes normally but is too stiff) - Your heart squeezes with normal or near-normal function (ejection fraction 50% or above) - Your blood markers for heart failure (BNP or NT-proBNP) are elevated **You may NOT be eligible if...** - Your heart's squeezing function has ever been below 49% (meaning you have a different type of heart failure) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.